{"disease":{"id":"impetigo","name":"Impetigo","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"cefuroxime-axetil","indication_name":"Impetigo","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftin","generic_name":"CEFUROXIME AXETIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":50,"revenue":null,"mechanism":"Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"retapamulin","indication_name":"Impetigo","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Altabax","generic_name":"RETAPAMULIN","company_name":"Almirall","drug_phase":"marketed","molecular_target":"","drug_class":"Pleuromutilin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime","indication_name":"Impetigo","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"mupirocin","indication_name":"Impetigo","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bactroban","generic_name":"MUPIROCIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"Isoleucine--tRNA ligase, cytoplasmic","drug_class":"RNA Synthetase Inhibitor Antibacterial","quality_score":75,"revenue":null,"mechanism":"Bactroban works by inhibiting the production of essential proteins in bacteria, preventing them from reproducing and causing infection."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03177993","title":"Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji","phase":"NA","overall_status":"COMPLETED","enrollment_count":4773,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT05226260","title":"Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":1634,"lead_sponsor_name":"Nationwide Children's Hospital","has_results":false},{"nct_id":"NCT03429595","title":"Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"UNION therapeutics","has_results":false},{"nct_id":"NCT07428915","title":"Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"AI Labs Group S.L","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}